Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg highlights 'attractive opportunity' for RWS investors

(Sharecast News) - Berenberg has maintained a 'buy' rating for RWS after the company introduced a "compelling" new growth strategy on Tuesday. Alonside its half-year results, which were already flagged in a trading update in April, the corporate content solutions group delivered a fresh strategy.

This included a new, simplified go-to-market positioning with regional sales teams and a tech-first proposition, and the reorganisation of the business into three units: Generate (content tech and TrainAI); Transform (localisation businesses); and Protect (IP services).

"We think this new, simplified messaging and go-to-market strategy around RWS's value-add proposition should be well received by investors, while also marking impressive progress under new CEO Ben Faes, who joined in January 2025," Berenberg said.

"With clear upcoming milestones as the strategy is put into action and new KPIs and medium-term guidance are announced, we think a valuation of 6.9x FY26 P/E and 3.5x FY26 EV/EBITDA offers an attractive opportunity for investors as the equity story rebuilds momentum."

The broker has a 240p target price for the stock, suggesting significant upside from Tuesday's 86.5p level, up 1.5% on the day.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.